Clostridioides (Clostridium) difficile infection: Review of literature

George Trad 1, 5, 6, *, Varun Sodhi 2, 5, 6, Matthew Brockway 3, 5, 6, Nazanin Sheikhan 1, 5, 6, Abdul Gader Gheriani 2, 5, 6, Olivia Astor 1, 5, 6 and Hatim Gemil 4, 5, 6

1 PGY2, Department of Internal Medicine Sunrise Health GME Consortium 2880 N Tenaya Way 2nd Floor Las Vegas, NV, USA.
2 PGY3, Department of Internal Medicine Sunrise Health GME Consortium Las Vegas, NV, USA 3PGY1, Department of Internal Medicine Sunrise Health GME Consortium Las Vegas, NV, USA.
3 PGY1, Department of Internal Medicine Sunrise Health GME Consortium Las Vegas, NV, USA.
4 Faculty Attending, Department of Internal Medicine Sunrise Health GME Consortium Las Vegas, NV, USA.
5 Mountain View Medical Center.
6 HCA Healthcare, Nashville TN.
 
Review Article
World Journal of Advanced Research and Reviews, 2022, 14(02), 146–155
Article DOI: 10.30574/wjarr.2022.14.2.0366
 
Publication history: 
Received on 22 March 2022; revised on 26 April 2022; accepted on 28 April 2022
 
Abstract: 
Clostridioides (Clostridium) difficile (C. difficile) is a gram-positive bacterium that infects the large intestine. The number of clostridium difficile infections has increased in the recent years due to multiple risk factors including frequent use of antibiotics and proton pump inhibitors. The virulence of C. difficile comes from its production of toxins. Treatment for C. difficile infection includes the use of antibiotics, monoclonal antibodies, or a fecal transplant.
 
Keywords: 
Clostridioides Difficile; Clostridium difficile; Antibiotics; Toxin; Diagnosis; Treatment; Monoclonal Antibodies
 
Full text article in PDF: 
 
Copyright information: 
Copyright © 2022 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0

 

Share this